Full Recording of the October 2025 ICARE Genetics Case Conference

Value of the Information & Strength of the Argument

The video provides substantial value by offering an expert synthesis of the latest evidence on moderate-risk ovarian cancer genes. Dr. Hanson systematically reviews key studies, including the 2010 discovery of RAD51C, the 2015 Song et al. case-control study, the 2020 international family study, and the 2021 Dorling et al. meta-analysis. She clearly explains how evidence has evolved, correcting earlier assumptions about breast cancer associations. The argumentation is solid, with each claim supported by specific citations and data. The discussion of risk thresholds and the impact of family history is particularly valuable for clinicians. The case presentation adds practical context, illustrating how to apply these risk estimates in a real patient scenario. The emphasis on individualized risk assessment is well-argued, acknowledging the limitations of current guidelines.

Scientific Rigor, Source Quality, Title Accuracy

The scientific rigor is high, as the presentation is based on a recently published ACMG clinical practice resource co-authored by the speaker. Dr. Hanson cites multiple peer-reviewed studies, including those by Loveday, Song, Yang, Dorling, and others, providing a comprehensive overview. The sources are credible and directly relevant. The title accurately reflects the content, as it is indeed a full recording of a genetics case conference. The description mentions the ACMG resource, and the speaker references it throughout. The video does not contain any obvious commercial bias, and the discussion is balanced. The case presentation is well-integrated, and the expert commentary is evidence-based. Overall, the sources are of high quality and appropriately used.

The title accurately reflects the content: a full recording of a genetics case conference, with a focus on RAD51C, RAD51D, and BRIP1 updates.

8/10

The conference features a recognized expert in clinical genetics (Dr. Helen Hanson) and is based on a recently published ACMG clinical practice resource. The discussion is grounded in peer-reviewed literature, though it is primarily an expert opinion and case-based discussion rather than a systematic review.

Markers derived by PSI from the transcript: the creator did not define chapters.

• 02:00Introduction and housekeeping announcements by Dr. Top Pal.
• 05:00Case presentation by Brenda: 42-year-old with BRIP1 mutation.
• 10:00Dr. Hanson begins her presentation on RAD51C, RAD51D, and BRIP1.
• 20:00Discussion of historical discovery and cancer risk evidence.
• 30:00Review of ovarian cancer risk management and thresholds.
• 40:00Breast cancer risk and management for RAD51C/D.
• 50:00Q&A and case discussions.

• ACMG clinical practice resource on RAD51C/D and BRIP1 — Mentioned as recently published and co-led by Dr. Hanson.
• ICARE social media — Mentioned as a resource for updates.

• ACMG clinical practice resource — The speaker co-authored this resource, and the presentation aligns with its recommendations.